Literature DB >> 31826990

Loss of Resistance to Mousepox during Chronic Lymphocytic Choriomeningitis Virus Infection Is Associated with Impaired T-Cell Responses and Can Be Rescued by Immunization.

Pedro Alves-Peixoto1,2,3, Maria Férez1, Cory J Knudson1, Carolina R Melo-Silva1, Colby Stotesbury1, Eric B Wong1, Margarida Correia-Neves2,3, Luis J Sigal4.   

Abstract

It is well established that chronic viral infections can cause immune suppression, resulting in increased susceptibility to other infectious diseases. However, the effects of chronic viral infection on T-cell responses and vaccination against highly pathogenic viruses are not well understood. We have recently shown that C57BL/6 (B6) mice lose their natural resistance to wild-type (WT) ectromelia virus (ECTV) when chronically infected with lymphocytic choriomeningitis virus (LCMV) clone 13 (CL13). Here we compared the T-cell response to ECTV in previously immunologically naive mice that were chronically infected with CL13 or that were convalescent from acute infection with the Armstrong (Arm) strain of LCMV. Our results show that mice that were chronically infected with CL13 but not those that had recovered from Arm infection have highly defective ECTV-specific CD8+ and CD4+ T-cell responses to WT ECTV. These defects are at least partly due to the chronic infection environment. In contrast to mice infected with WT ECTV, mice chronically infected with CL13 survived without signs of disease when infected with ECTV-Δ036, a mutant ECTV strain that is highly attenuated. Strikingly, mice chronically infected with CL13 mounted a strong CD8+ T-cell response to ECTV-Δ036 and survived without signs of disease after a subsequent challenge with WT ECTV. Our work suggests that enhanced susceptibility to acute viral infections in chronically infected individuals can be partly due to poor T-cell responses but that sufficient T-cell function can be recovered and resistance to acute infection can be restored by immunization with highly attenuated vaccines.IMPORTANCE Chronic viral infections may result in immunosuppression and enhanced susceptibility to infections with other pathogens. For example, we have recently shown that mice chronically infected with lymphocytic choriomeningitis virus (LCMV) clone 13 (CL13) are highly susceptible to mousepox, a disease that is caused by ectromelia virus and that is the mouse homolog of human smallpox. Here we show chronic CL13 infection severely disrupts the expansion, proliferation, activation, and cytotoxicity of T cells in response due at least in part to the suppressive effects of the chronic infection milieu. Notably, despite this profound immunodeficiency, mice chronically infected with CL13 could be protected by vaccination with a highly attenuated variant of ECTV. These results demonstrate that protective vaccination of immunosuppressed individuals is possible, provided that proper immunization tools are used.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  T cells; ectromelia virus; immunization; lymphocytic choriomeningitis virus; poxvirus

Year:  2020        PMID: 31826990      PMCID: PMC7022357          DOI: 10.1128/JVI.01832-19

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor.

Authors:  Nikhil S Joshi; Weiguo Cui; Anmol Chandele; Heung Kyu Lee; David R Urso; James Hagman; Laurent Gapin; Susan M Kaech
Journal:  Immunity       Date:  2007-08       Impact factor: 31.745

2.  Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus.

Authors:  R O Jacoby; P N Bhatt; D G Brownstein
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

3.  Antibodies and CD8+ T cells are complementary and essential for natural resistance to a highly lethal cytopathic virus.

Authors:  Min Fang; Luis J Sigal
Journal:  J Immunol       Date:  2005-11-15       Impact factor: 5.422

4.  Virus-induced immunosuppression. 1. Age at infection relates to a selective or generalized defect.

Authors:  A Tishon; P Borrow; C Evans; M B Oldstone
Journal:  Virology       Date:  1993-08       Impact factor: 3.616

5.  Critical role for alpha/beta and gamma interferons in persistence of lymphocytic choriomeningitis virus by clonal exhaustion of cytotoxic T cells.

Authors:  R Ou; S Zhou; L Huang; D Moskophidis
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

6.  Restoring function in exhausted CD8 T cells during chronic viral infection.

Authors:  Daniel L Barber; E John Wherry; David Masopust; Baogong Zhu; James P Allison; Arlene H Sharpe; Gordon J Freeman; Rafi Ahmed
Journal:  Nature       Date:  2005-12-28       Impact factor: 49.962

Review 7.  Type I Interferon in Chronic Virus Infection and Cancer.

Authors:  Laura M Snell; Tracy L McGaha; David G Brooks
Journal:  Trends Immunol       Date:  2017-05-31       Impact factor: 16.687

Review 8.  The Pathogenesis and Immunobiology of Mousepox.

Authors:  Luis J Sigal
Journal:  Adv Immunol       Date:  2015-11-21       Impact factor: 3.543

9.  Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression.

Authors:  P Borrow; C F Evans; M B Oldstone
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations.

Authors:  L K Selin; S M Varga; I C Wong; R M Welsh
Journal:  J Exp Med       Date:  1998-11-02       Impact factor: 14.307

View more
  1 in total

1.  Chronic Lymphocytic Choriomeningitis Infection Causes Susceptibility to Mousepox and Impairs Natural Killer Cell Maturation and Function.

Authors:  Pedro Alves-Peixoto; Maria Férez; Cory J Knudson; Colby Stotesbury; Carolina R Melo-Silva; Eric B Wong; Margarida Correia-Neves; Luis J Sigal
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.